News Conference News ACC 2023 Short DAPT Noninferior to 1 Year After Ultrathin DES PCI: HOST-IDEA Yael L. Maxwell March 09, 2023
News Conference News ACC 2023 Viability Testing Fails to Find HF Patients Who’d Benefit From PCI in REVIVED-BCIS2 Michael O'Riordan March 09, 2023
News Conference News ACC 2021 Complete Revascularization Analysis of ISCHEMIA Opens ‘Pandora’s Box’ Michael O'Riordan May 18, 2021
News Conference News ACC 2020 VOYAGER PAD: Rivaroxaban Bests Aspirin Alone for Preventing Limb and CV Events L.A. McKeown March 28, 2020
News Conference News ACC 2020 More Symptoms, Less Extensive Disease in Women With Stable CAD: ISCHEMIA Michael O'Riordan March 28, 2020
News Conference News ACC 2019 Ticagrelor Monotherapy Noninferior to DAPT After PCI in Adjudicated-Events Analysis: GLASSY Yael L. Maxwell March 27, 2019
News Conference News ACC 2018 ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last Shelley Wood March 05, 2018
News Conference News ACC 2014 ZES Plus Tailored Course of Dual Therapy Reduces Adverse Events in Unlikely DES Candidates Yael L. Maxwell March 31, 2014
News Conference News ACC 2014 NEXT at 2 Years: Nobori DES Still Noninferior to Xience/Promus Jason Kahn March 31, 2014
News Conference News ACC 2013 Is Nobori NEXT? Biodegradable-Polymer DES Noninferior to EES Jason Kahn March 09, 2013
News Conference News ACC 2012 CPORT-E: PCI Outcomes Similar Regardless of On-Site Cardiac Surgery March 25, 2012